# A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

> **NCT04543188** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 65 (actual)

## Conditions studied

- Malignant Melanoma
- Carcinoma, Non-Small-Cell Lung
- Brain Neoplasms, Primary
- Brain Neoplasms
- Malignant Neoplasms

## Interventions

- **DRUG:** PF-07284890
- **DRUG:** Binimetinib
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT04543188
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-08
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543188, "A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04543188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*